Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Αgainst Medullary Thyroid Cancer?

Damaskos, Christos; Valsami, Serena; Spartalis, Eleftherios; Antoniou, Efstathios; Tomos, Periklis; Karamaroudis, Stefanos; Zoumpou, Theofano; Pergialiotis, Vasilios; Stergios, Konstantinos; Michaelides, Constantinos; Kontzoglou, Konstantinos; Perrea, Despina; Nikiteas, Nikolaos; Dimitroulis, Dimitrios

doi:10.21873/anticanres.11070

Cited by 26 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials using HDAC inhibitors have been performed and their results indicate that HDAC inhibitors have antitumor activity (14,(36)(37)(38)(39)(40) and may be clinically beneficial. For example, SAHA/vorinostat and romidepsin were approved by the US Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (36,37) and peripheral T-cell lymphoma (38) respectively.…”

Section: Hdac Inhibitors As Anti-breast Cancer Agentsmentioning

confidence: 99%

Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer

Damaskos

Valsami

Kontos

et al. 2017

Self Cite

167

151

View full text Add to dashboard Cite

Abstract. With a lifetime risk estimated to be one in eight in industrialized countriesBreast cancer is the most frequently diagnosed cancer and the second leading cause of cancer-related death among women worldwide. According to the American Cancer Society about 12% U.S. women will develop breast cancer during their lifetime. Moreover, in 2015, about 2,300 men were diagnosed with breast cancer and 440 died from the disease (1, 2).In approximately 90% of breast cancer cases, estrogen receptor α (ERα), progesterone receptor (PR), or the human epidermal growth factor receptor2 (HER2/ERBB2) protooncogenic receptor are expressed. In many of these patients, treatment with anti-estrogens (e.g. aromatase inhibitors, tamoxifen, fulvestrant) and HER2-targeted agents has improved their survival significantly (3, 4). However, despite 35

show abstract

Section: Hdac Inhibitors As Anti-breast Cancer Agentsmentioning

confidence: 99%

Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer

Damaskos

Valsami

Kontos

et al. 2017

Self Cite

167

151

View full text Add to dashboard Cite

show abstract

“…Clinical trials (phases I and II) have also demonstrated that HDAC inhibitors result in minor adverse effects in patients (15,(26)(27)(28)(29)(30). Their mechanism of action involves binding of their hydroxamate group to the zinc cation (Zn 2+ ) located in the HDAC cavity (31).…”

Section: Hdac Inhibitors As Anti-cancer Agentsmentioning

confidence: 99%

Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises

2017

CGP

View full text Add to dashboard Cite

show abstract

“…Clinical trials of other HDACIs are underway, while several studies have demonstrated their important anticancer effects, highlighting their action against malignancies such as pancreatic, breast, medullary thyroid, and non-small cell lung cancer (21,(29)(30)(31)(32)(33).…”

Section: Hdaci and Their Effects In Ummentioning

confidence: 99%

The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence

et al. 2018

Self Cite

View full text Add to dashboard Cite

Uveal melanoma is the most common intraocular malignancy in adults, representing approximately 3% of all melanoma cases. Despite progress in chemotherapy, radiation and surgical treatment options, the prognosis and survival rates remain poor. Acetylation of histone proteins causes transcription of genes involved in cell growth, DNA replication and progression of cell cycle. Overexpression of histone deacetylases occurs in a wide spectrum of malignancies. Histone deacetylase inhibitors block the action of histone deacetylases, leading to inhibition of tumor cell proliferation. This article reviewed the potential therapeutic effects of histone deacetylase inhibitors on uveal melanoma. MEDLINE database was used under the key words/phrases: histone deacetylase, inhibitors, uveal melanoma and targeted therapies for uveal melanoma. A total of 47, English articles, not only referring to uveal melanoma, published up to February 2018 were used. Valproic acid, trichostatin A, tenovin-6, depsipeptide, panobinostat (LBH-589), vorinostat (suberanilohydroxamic acid) entinostat (MS-275), quisinostat, NaB, JSL-1, MC1568 and MC1575 are histone deacetylase inhibitors that have demonstrated promising antitumor effects against uveal melanoma. Histone deacetylase inhibitors represent a promising therapeutic approach for the treatment of uveal melanoma.

show abstract

Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Αgainst Medullary Thyroid Cancer?

Abstract: Abstract. Background

Cited by 26 publications

References 26 publications

Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer

Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer

Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises

The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence

Contact Info

Product

Resources

About